Cowen Raises Price Target on Aquinox Pharma (AQXP) Following R&D Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Leerink Partners Remains Bullish on Aquinox Pharma (AQXP) Following Investor Day
October 8, 2015 8:32 AM EDTLeerink Partners reiterated an Outperform rating and $26.00 price target on Aquinox Pharmaceutical (NASDAQ: AQXP) after attending an investor day. At the event, the company unveiled the AQX-1125 Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) Phase III design it plans propose to FDA at its endof-Phase II meeting in 4Q15.
Analyst Paul Matteis commented,... More
